Navigation Links
Genzyme to Build New R&D Center in Beijing
Date:4/22/2008

Environmentally Responsible Site to Significantly Increase Company's

Presence in China

CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.

The new facility will be used for research and development activities involving many of Genzyme's key areas of focus, including orthopedics, transplant and immune disease, oncology, endocrinology and cardiovascular disease. The facility, which will feature an innovative green design, will also include laboratory-scale operations for the MACI(R) (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations.

"This new site represents a major step forward in our effort to improve the lives of patients in China by introducing innovative new medical products," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "As we expand our presence in China, we look forward to making a significant contribution to the growth of the country's life sciences industry."

Genzyme already markets Synvisc(R) (hylan G-F 20) and Thymoglobulin(R) (anti-thymocyte globulin rabbit) in China, and is preparing to introduce additional products next year. The company also has a pilot program at Beijing Wujing Hospital for the cell therapy product MACI. Genzyme currently has 25 employees working in offices in Beijing and Shanghai.

Since 1999, Genzyme has provided its rare genetic disease treatment Cerezyme(R) (imiglucerase for injection) free of charge to Chinese patients in need. Approximately 125 patients are being treated in China through the Gaucher Initiative, Genzyme's humanitarian partnership with Project HOPE. Last year, the company began a collaboration with the Chinese firm Sunway Biotech Co. Ltd. with the goal of bringing a gene therapy for cardiovascular disease to patients in China and Genzyme is seeking to form additional partnerships with local companies.

Consistent with Genzyme's commitment to the environment and corporate responsibility, the new Beijing facility will feature an attractive architectural design and innovative green features that will create a healthy and comfortable workplace for employees, and reduce its environmental impact. The company intends to seek certification for the building with the U.S. Green Building Council's Leadership in Energy and Environmental Design (LEED) rating system. Genzyme's global corporate headquarters, Genzyme Center, achieved the highest LEED rating, and all of the company's facilities worldwide are being built to high environmental standards. Genzyme is conducting major R&D and manufacturing expansion projects in the United States, Belgium, France, the United Kingdom and the Netherlands, and is rapidly expanding its commercial operations in countries around the world.

Genzyme's new Beijing facility will be located in Zhongguancun (ZGC) Life Science Park, an area dedicated to academic and government research centers as well as pharmaceutical and biotechnology companies. The 200,000 square-foot building will be constructed with low-impact environmental techniques and methods, and will incorporate a range of environmentally responsible features, including: a living roof to reduce pollution caused by storm water runoff; a solar thermal system that will provide a significant portion of the building's hot water and reduce its energy consumption; and low-flow fixtures to limit water usage.

An all-glass exterior will provide employees with significant natural light, contributing to a pleasant working environment and reducing the facility's dependence on electricity for artificial lighting. The facility is also intended to serve as a central gathering spot, with a large auditorium to host meetings of employees, physicians and others in the scientific community. This meeting space will be adjacent to an exterior garden area, and there will also be interior gardens throughout the facility.

Genzyme's core research and development operations are located in Massachusetts, USA. The company also has a research site in Cambridge, U.K. The Beijing facility will be the company's second product-focused R&D site outside of the United States.

Genzyme is seeking necessary governmental authorizations and expects to complete and open the facility in 2010. The facility will be able to accommodate 350 employees, and the total cost for the project is estimated to be $90 million. The architect is RMJM Hillier and the engineer is MW Zander.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements regarding Genzyme's business plans and strategies, including without limitation: the construction of an R&D facility in Beijing, the incorporation of environmentally sensitive design features and construction techniques into the facility, the commencement of construction of the facility, and the completion and opening of the facility in 2010. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to obtain all required authorizations and permits to build the R&D facility; Genzyme's ability to utilize low impact environmental techniques and to incorporate environmentally sensitive design features into the facility; Genzyme's ability to construct the facility without delays resulting from customary design and construction risks; Genzyme's ability to validate, set-up and commence operations at the facility; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the period ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Synvisc(R), Thymoglobulin(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Erin Emlock Patrick Flanigan

(617) 768-6579 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme Provides Update on Myozyme(R) Manufacturing
2. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
3. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
4. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
5. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
6. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
7. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
8. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
(Date:2/5/2016)... SAN FRANCISCO , February 5, 2016 ... AMBS), a biotechnology company focused on developing products ... it has requested Rare Pediatric Disease Designation (RPDD) from ... retinitis pigmentosa (RP) with MANF. MANF was previously granted ... December 2014. --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... , ... February 04, 2016 , ... ... development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Sangamo BioSciences, ... genome editing, announced today that Edward Lanphier , ... update on the progress of Sangamo,s ZFP Therapeutic ® ... business strategy at 2:40 pm ET on Thursday, February ... Annual Global Healthcare Conference. The conference is being held ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
Breaking Biology News(10 mins):